Graham served as Chairman of the Department of Chemistry at Oxford University. Throughout his career, he has been involved in the commercialization of technologies where he was a director of the University of Oxford's technology transfer company. He was also involved with the Wellcome Trust in a similar capacity. He co-founded Oxford Molecular Group plc and InhibOx Ltd. He was a main board director, now venture partner, of IP Group plc, the listed intellectual property commercialization company.
Paul completed his undergraduate degree at St Peter's College, Oxford and his biochemistry Ph.D. at the University of Manchester. He has worked as a computational chemistry for SmithKline Beecham and Pfizer. Paul was group director of R&D at TopoTarget. He led the histone deacetylase inhibitor programme through discovery and pre-clinical development, and is co-inventor of Belinostat, which was approved by the FDA for the treatment of peripheral T-cell lymphoma in 2014.
After a degree and Ph.D. at the University of St. Andrews, Michael worked as a computational chemist at Zeneca Specialties. He then set up the computational chemistry group at Evotec before moving to Chroma Therapeutics as head of computational chemistry. He managed the early stage of one of the inflammation projects and worked on reviewing new drug targets. He also sat on the project review team, which made key decisions on project direction. Michael joinied InhibOx in 2013, playing a key role in compound design for the antibacterial project.
Grace completed her undergraduate degree at the University of Durham. She completed her masters year while working as an industrial trainee at Pfizer, Sandwich. She completed her Ph.D in computational chemistry at the University of Surrey. In 2014, Grace worked as a research fellow at the University of Surrey in collaboration with Defence Science and Technology Laboratory (DSTL) in the area of polymer modelling. She joined InhibOx in 2015, working on antibacterial drug design.